Ir para o conteúdo principal

Corbus Pharmaceuticals Holding (NASDAQ: CRBP) — Perfil da empresa, notícias e dados financeiros

Logo de Corbus Pharmaceuticals Holding
CRBP Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holding primary media
Perfil da empresa

Corbus Pharmaceuticals Holding

Corbus Pharmaceuticals (NASDAQ:CRBP) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Their research is geared towards discovering and developing drugs that target the endocannabinoid system, aiming to provide innovative treatments for conditions with significant unmet medical needs. Corbus's key projects include advanced clinical trials for treatments in diseases such as systemic sclerosis and dermatomyositis. The objective of the company is to leverage its expertise in drug development to bring new, effective therapies to market, improving the lives of patients worldwide. With a dedicated team and a passion for science, Corbus strives to make a lasting impact in the field of medicine through its research and development efforts.

Resumo

Public USParticipação acionária
2009Ano de fundação
43Funcionários
Norwood, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Corbus Pharmaceuticals Holding

  • Lenabasum, an orally administered drug intended for the treatment of systemic sclerosis and dermatomyositis.
  • CRB-4001, aimed to prevent fibrosis and treat related diseases by targeting the CB1 receptor.
  • CRB-022, an early-stage development project focusing on anti-inflammatory and fibrotic diseases.
  • Bacteriophage therapies, exploring natural virus-based treatments targeting resistant bacterial infections in partnership with leading institutions.
  • Pipeline expansion strategy, actively seeking in-licensing opportunities and collaborations to enhance the portfolio of treatments for inflammatory and fibrotic diseases.

equipe executiva do Corbus Pharmaceuticals Holding

  • Yuval CohenCEO & Director
  • Sean F. MoranChief Financial Officer
  • Ian HodgsonChief Operating Officer
  • G. Scott GoekenGeneral Counsel & Corporate Secretary
  • Christina BertschVice President of Human Resources
  • Nishant C. SaxenaChief Business Officer
  • Leonardo Viana NicacioChief Medical Officer

Principais indicadores financeiros

Resultados divulgados pela Corbus Pharmaceuticals Holding, em USD.

Cap. de mercado
80,3 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-6.1
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Corbus Pharmaceuticals Holding
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-85,3 mi-78,5 mi
0-48,7 mi-40,2 mi
0-45,1 mi-44,6 mi
0-34,8 mi-55,8 mi